() said it has been granted a European Union-wide patent covering the production process for its G+ graphene nanoplatelets with a priority date of June 20, 2014.
The AIM-listed firm said the patent covers the use of its unique water-based exfoliation technology for converting super-expanded graphite to pristine graphene nanoplatelets using no chemicals and with a very high conversion yield.
Directa added that following the grant of the patent, its intellectual portfolio will comprise 16 patent families with 48 patents granted and 20 patents pending.
“This grant means that our unique production process is now patented and that we have created a significant barrier to entry for competitors seeking to replicate our chemical-free technology. We will continue to build our IP portfolio, covering both production technology and applications in order to continue to build value for shareholders,” Directa Plus founder and chief executive Giulio Cesareo said in a statement.